332 related articles for article (PubMed ID: 28103289)
1. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France.
Baro E; Galperine T; Denies F; Lannoy D; Lenne X; Odou P; Guery B; Dervaux B
PLoS One; 2017; 12(1):e0170258. PubMed ID: 28103289
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.
Merlo G; Graves N; Brain D; Connelly LB
J Gastroenterol Hepatol; 2016 Dec; 31(12):1927-1932. PubMed ID: 27043242
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection.
Varier RU; Biltaji E; Smith KJ; Roberts MS; Kyle Jensen M; LaFleur J; Nelson RE
Infect Control Hosp Epidemiol; 2015 Apr; 36(4):438-44. PubMed ID: 25782899
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection.
Varier RU; Biltaji E; Smith KJ; Roberts MS; Jensen MK; LaFleur J; Nelson RE
Clin Microbiol Infect; 2014 Dec; 20(12):1343-51. PubMed ID: 25366338
[TBL] [Abstract][Full Text] [Related]
5. Fecal Transplants by Colonoscopy and Capsules Are Cost-Effective Strategies for Treating Recurrent Clostridioides difficile Infection.
Luo Y; Lucas AL; Grinspan AM
Dig Dis Sci; 2020 Apr; 65(4):1125-1133. PubMed ID: 31493042
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection.
Lapointe-Shaw L; Tran KL; Coyte PC; Hancock-Howard RL; Powis J; Poutanen SM; Hota S
PLoS One; 2016; 11(2):e0149521. PubMed ID: 26901316
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis.
Konijeti GG; Sauk J; Shrime MG; Gupta M; Ananthakrishnan AN
Clin Infect Dis; 2014 Jun; 58(11):1507-14. PubMed ID: 24692533
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States.
Stranges PM; Hutton DW; Collins CD
Value Health; 2013; 16(2):297-304. PubMed ID: 23538181
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of ribotype-guided fecal microbiota transplantation in Chinese patients with severe Clostridium difficile infection.
Jiang M; Leung NH; Ip M; You JHS
PLoS One; 2018; 13(7):e0201539. PubMed ID: 30048534
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
Watt M; Dinh A; Le Monnier A; Tilleul P
J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
You JHS; Jiang X; Lee WH; Chan PKS; Ng SC
J Gastroenterol Hepatol; 2020 Sep; 35(9):1515-1523. PubMed ID: 32017248
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Fecal Microbiota Transplantation for First Recurrent Clostridioides difficile Infection.
Aby ES; Vaughn BP; Enns EA; Rajasingham R
Clin Infect Dis; 2022 Oct; 75(9):1602-1609. PubMed ID: 35275989
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in Japan.
Okumura H; Ueyama M; Shoji S; English M
J Infect Chemother; 2020 Jun; 26(6):611-618. PubMed ID: 32165072
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of a fecal microbiota transplant center for treating recurrent C.difficile infection.
Shaffer SR; Witt J; Targownik LE; Kao D; Lee C; Smieliauskas F; Rubin DT; Singh H; Bernstein CN
J Infect; 2020 Nov; 81(5):758-765. PubMed ID: 32980389
[TBL] [Abstract][Full Text] [Related]
17. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
18. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions.
Ianiro G; Masucci L; Quaranta G; Simonelli C; Lopetuso LR; Sanguinetti M; Gasbarrini A; Cammarota G
Aliment Pharmacol Ther; 2018 Jul; 48(2):152-159. PubMed ID: 29851107
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
Brandt LJ; Aroniadis OC; Mellow M; Kanatzar A; Kelly C; Park T; Stollman N; Rohlke F; Surawicz C
Am J Gastroenterol; 2012 Jul; 107(7):1079-87. PubMed ID: 22450732
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of Faecal microbiota transplantation compared to antibiotics for the treatment of recurrent
Abdali ZI; Roberts TE; Barton P; Hawkey PM
EClinicalMedicine; 2020 Jul; 24():100420. PubMed ID: 32637898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
